PSUMMIT-1 and 2 Study Groups

Author PubWeight™ 1.74^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials.	Ann Rheum Dis	2014	1.80